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Abstract: Several reports suggested a role of heme oxygenase genes 1
and 2 (HMOX1 and HMOX2) in modifying the risk to develop Parkinson
disease (PD). Because essential tremor (ET) and PD share phenotypical
and, probably, etiologic factors of the similarities, we analyzed whether
such genes are related with the risk to develop ET.
We analyzed the distribution of allelic and genotype frequencies of
the HMOX1 rs2071746, HMOX1 rs2071747, HMOX2 rs2270363, and
HMOX2 rs1051308 single nucleotide polymorphisms, as well as the
presence of copy number variations of these genes in 202 subjects with
familial ET and 747 healthy controls.
Allelic frequencies of rs2071746T and rs1051308G were signifi-
cantly lower in ET patients than in controls. None of the studied
polymorphisms influenced the disease onset.
The present study suggests a weak association between HMOX1
rs2071746 and HMOX2 rs1051308 polymorphisms and the risk to
develop ET in the Spanish population.
(Medicine 94(24):e968)
Abbreviations: (GT)n = alternating purine-pyrimidine sequence,
CNV = copy number variation, ET = essential tremor, HMOX =
heme oxygenase, PD = Parkinson disease, SNP = single nucleotide
polymorphism.
INTRODUCTION
D espite the role of genetic factors in the pathogenesis ofessential tremor (ET) is supported by substantial evidence,
the identification of the responsible gene(s) remains to be
clarified (revised in references).1,2
Heme oxygenase (HMOX) is an essential enzyme in heme
catabolism, and it occurs as 2 main isozymes, an inducible heme
oxygenase-1 (HMOX1) and a constitutive heme oxygenase-2
(HMOX2), which are encoded by the genes designated, respect-
ively, as HMOX1, HO-1, or HSP32 (gene identity 3162,
chromosome 22q13.1) and HMOX2 or HO-2 (gene identity
3163, chromosome 16p13.3).
Recently, several studies have shown association between
HMOX genes and the risk for Parkinson disease (PD). Although
Funke et al3 found no association between 4 genetic markers of
HMOX1 with susceptibility for PD, other group found a syner-
gistic association of HMOX1 rs2077146TT genotype both with
glycogen synthase kinase 3-beta (GSK3beta) gene4 and with
pesticides exposure,5 increasing the risk for PD. We previously
reported an association between the variable number tandem
repeat of alternating purine-pyrimidine sequence (GT)n and the
single nucleotide polymorphism (SNP) rs2071746 in the
HMOX1 gene with the risk of developing PD, especially with
early onset of the disease and with the classic PD phenotype,
whereas rs2071747 and rs9282702 SNPs showed no associ-
ation.6 With regards of the HMOX2 gene, our group reported an
increased risk for PD among rs2270363GG carriers, and lack of
association with rs17884623 and rs17880805 SNPs.7
Because ET and PD are 2 common disorders that share
many epidemiologic, genetic, clinical, neuroimaging, and neu-
ropathological features,8–10 it seems reasonable to study the
possible association between SNPs previously associated with
PD risk, and the risk for ET. To investigate a possible associ-
ation between HMOX1 and HMOX2 polymorphism and the risk
of developing ET, we genotyped HMOX1 and HMOX2 SNPs in
a large group of white Spanish ET patients and controls.
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METHODS
ET Patients and Controls
The 202 patients included in the study fulfilled the diag-
nostic criteria for definite ET11 (100 men and 102 women, mean
age 65.7 16.1, mean age at onset of ET 48.2 18.1 years), and
747 age- and sex-matched controls (379 men and 368 women,
mean age 63.6 14.6 years). ET patients were recruited from
the Movement Disorders Units of 3 University Hospitals.
Inclusion criteria, beside the diagnosis of definite ET, were
the absence of other previous neurological diseases, positive
family history of ET (at least 1 first-degree relative affected),
and normal thyroid function. Controls were healthy unrelated
age- and sex-matched white Spanish individuals who did not
have tremor or other movement disorders (459 were recruited
from the Clı́nica Universitaria de Navarra, Pamplona, Spain;
and 288 were recruited from the Infanta Cristina University
Hospital, Badajoz, Spain).
Ethical Aspects
All the participants were included in the study after giving
written informed consent. This study was approved by the ethics
committees of the University Hospital ‘‘Prı́ncipe de Asturias’’
(University of Alcalá, Alcalá de Henares, Madrid, Spain), the
Infanta Cristina University Hospital (Badajoz, Spain), and
Clı́nica Universitaria de Navarra (Pamplona, Spain). The study
was conducted according to the principles expressed in the
declaration of Helsinki.
Genotyping
Two SNPs in the HMOX1 gene and 2 polymorphisms in the
HMOX2 gene were genotyped by means of TaqMan probes.
Analyses included the HMOX1 SNP rs2071746, which is an
upstream variant, HMOX1 rs2071747, which is a missense
mutation within the exon 1 of the HMOX1 gene, the SNP
rs2270363, which is a polymorphism in the regulatory region
of the human HMOX2 gene, and rs1051308 is a polymorphism
in the 3’untranslated region. These SNPs were selected on the
basis of expected allele frequency in white individuals and
putative functional effects.6,7
Genotyping was performed in genomic DNA obtained
from blood samples of participants and was carried out by
means of TaqMan assays (Applied Biosciences Hispania, Alco-
bendas, Madrid, Spain), which were designed to detect the
previously mentioned SNPs. Detection was carried out by
real-time quantitative polymerase chain reaction in an Eppen-
dorf RealPlex Thermocycler. The amplification conditions were
the following: a denaturation time of 10 minutes at 96 8C was
carried out, then 45 cycles of 92 8C 15 seconds 60 8C 90 seconds
were carried out, and fluorescence was measured at the end of
each cycle and at endpoint. All samples were determined in
triplicate. Genotypes were assigned by means of gene identi-
fication software (RealPlex 2.0; Eppendorf) and by analysis of
the reference cycle number for each fluorescence curve, calcu-
lated using the CalQPlex algorithm (Eppendorf).
Copy number variations (CNVs) were analyzed using the
TaqMan copy number assays of the HMOX1 and HMOX2 genes,
Hs00774483_cn and Hs01223070_cn, respectively. Both assays
were designed to hybridize within the open reading frame
within the target genes (Applied Biosciences Hispania, Alco-
bendas, Madrid, Spain). Amplification was carried out in an
Applied Biosystems 7500 real-time thermocycler as described
by the manufacturer, using RNAase P as a copy number
reference assay. All reactions were carried out in quadruplicate.
Results were analyzed by means of the CopyCaller Software
(Applied Biosciences Hispania). According to standard pro-
cedures in CNV analyses, samples with a single copy of the
corresponding gene were named as heterozygous (null/present).
Because the probes were designed to detect exonic sequences,
even if the rest of the gene would remain in these so-called null
alleles, the translated protein would not be functional.
Statistical Analysis
The Hardy–Weinberg equilibrium was analyzed with the
PLINK software.12 Haplotype reconstruction was performed
using the program PHASE v2.1.1.13 We used the default model
for recombination rate variation with 1000 iterations, 500 burn-
in iterations, and a thinning interval of 1. Further details are
provided elsewhere.14 Statistical analyses were performed using
the SPSS 15.0 for Windows (SPSS Inc, Chicago, IL). Intergroup
comparison values were calculated by using the x2 or Fisher
tests when appropriate. The 95% confidence intervals were also
calculated. Correction for multiple testing (Pc values) were
calculated by using the False discovery rate procedure.15
The sample size was determined from variant allele fre-
quencies observed in control individuals with a genetic model
analyzing the frequency for carriers of the disease gene with a
relative risk value 1.5 (P¼ 0.05). The statistical power for 2-
tailed associations for the presence of the SNPs identified in this
study (rs2071746, rs2071747, rs2270363, and rs1051308) was
95.06%, 38.51%, 92.72%, and 94.23%, respectively. Testing for
heterogeneous association (homogeneity test) was analyzed by
using the Breslow–Day test. The negative predictive value was
calculated as d/r2 (d¼ number of control individuals with the
risk factor absent, r2¼ sum of ET patients and controls with the
risk factor absent).
RESULTS
The frequencies of the rs2071746, rs2071747, rs2270363,
and rs1051308 genotypes and allelic variants in ET were in
Hardy–Weinberg equilibrium, both in ET patient and control
groups. The frequencies of rs2071746TT, and rs1051308GG
genotypes and rs2021746T and rs1051308G alleles were sig-
nificantly lower in ET patients than in controls, although, after
multiple test comparison analysis, only the differences for
rs2021746T and rs1051308G alleles remained as significant
(Table 1). The frequencies of rs2071747 and rs2270363 did not
differ significantly between ET patient and control groups.
The frequency of rs2071746TT genotype was significantly
lower in ET men than in control men, whereas that of
rs1051308GG genotype and rs1051308G allele were signifi-
cantly lower in ET women than in control women; however,
only the differences in rs1051308G allele frequency in women
remained significant after multiple test correction (Table 2).
MeanSD age at onset of tremor did not differ among the
ET carrying rs2071746AA, rs2071746AT, and rs2071746TT
genotypes (49.2 23.9, 47.3 26.2, and 47.6 17.3 years,
respectively); rs2071747GG and rs2071747GC genotypes
(48.1 26.5 and 45.5 11.2 years, respectively);
rs2270363GG, rs2270363GA, and rs2270363AA genotypes
(46.6 25.6, 49.8 25.3, and 47.0 15.2 years, respectively);
and rs1051308AA, rs1051308AG, and rs1051308AA genotypes
(47.6 26.7; 49.4 24.9, and 44.6 13.0 years, respectively).
The frequencies of the rs2071746, rs2071747, rs2270363,
and rs1051308 genotypes and allelic variants in ET patients
with head (n¼ 45), voice (n¼ 45), tongue (n¼ 16), and chin
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tremor (n¼ 11) did not differ significantly from those found in
the control group, after correcting for multiple comparison
analysis (data not shown).
CNV analyses revealed the occurrence of 2 control indi-
viduals with a single copy of HMOX1 and another 2 individuals
with a single copy of HMOX2. No CNVs were identified among
ET group (Table 1) Individuals with 0 or 2 gene copies were
not identified in the whole study group.
DISCUSSION
Data from the present study suggest a weak association
between the allelic variants HMOX1 rs2071746T and HMOX2
rs1051308G and the risk for ET. Previous studies reported also
association between these HMOX polymorphisms and PD.6,7
However, the possible putative mechanisms suggesting an
association between HMOX and ET should be considered as
speculative. In a previous study, we reported association
between a HMOX1 microsatellite (GT)n polymorphism and
the risk of developing PD.6 Such a microsatellite polymorphism
could not be analyzed in the present study because of DNA
shortage. CNVs analyses revealed that CNV variations occur
rarely in ET patients and that these gene variations do not seem
to play a major role regarding risk association.
In the brain, the HMOX pathway is very important as a
defensive mechanism for neurons exposed to oxidative stress,
contributing to the degradation of heme to biliverdin, free iron,
and carbon monoxide; and particularly HMOX1 expression has
been found upregulated in the brains of patients with PD,
Alzheimer disease, and multiple sclerosis.16,17 Moreover, upre-
gulation of HMOX1 in astrocytes increases neuronal oxidative
stress and sequestration of iron nonlinked to transferrin in the
mitochondrial department.17
Despite the predominant role of genetic factors in the
etiology of ET,1,2,18–22 the role of environmental factors alone
or interacting with genetic factors has been also suggested.22–24
Several years ago, our group conducted a case–control study on
the exposure to some environmental factors such as substances
TABLE 1. HMOX Genotypes and Allelic Variants of Patients With ET and Healthy Volunteers
ET Patients
(N¼ 202, 404 alleles)
Controls
(N¼ 747, 1494 alleles)
OR (95% CI), P;
NPV (95% CI)
Genotypes
HMOX1 rs2071746 A/A 68 (33.7, 27.1–40.2) 201 (26.9, 23.7–30.1) 1.38 (0.97–1.95), 0.059, 0.80 (0.79–0.82)
A/T 102 (50.5, 43.6–57.4) 374 (50.1, 46.5–53.7) 1.02 (0.74–1.41), 0.914, 0.79 (0.76–0.82)
T/T 32 (15.8, 10.8–20.9) 170 (22.8, 19.8–25.8) 0.64 (0.41–0.99), 0.033,

0.77 (0.76–0.79)
Null/A 0 (–) 1 (0.1, 0.1 to 0.4) –, 0.603, 0.79 (0.79–0.79)
Null/T 0 (–) 1 (0.1, 0.1 to 0.4) –, 0.603, 0.79 (0.79–0.79)
HMOX1 rs2071747 G/G 189 (93.6, 90.2–96.9) 680 (91.0, 89.0–93.1) 1.43 (0.75–2.79), 0.250, 0.84 (0.74–0.91)
G/C 13 (6.4, 3.1–9.8) 63 (8.4, 6.4–10.4) 0.75 (0.38–1.43), 0.354, 0.78 (0.78–0.79)
C/C 0 (–) 2 (0.3, 0.1 to 0.7) –, 0.462, 0.79 (0.79–0.79)
Null/G 0 (–) 2 (0.3, 0.1 to 0.7) –, 0.462, 0.79 (0.79–0.79)
Null/C 0 (–) 0 (–) —
HMOX2 rs2270363 G/G 92 (45.5, 38.7–52.4) 360 (48.2, 44.6–51.8) 0.90 (0.65–1.24), 0.504, 0.78 (0.75–0.81)
G/A 87 (43.1, 36.2–49.9) 317 (42.4, 38.9–46.0) 1.03 (0.74–1.42), 0.872, 0.79 (0.77–0.81)
A/A 23 (11.4, 7.0–15.8) 68 (9.1, 7.0–11.2) 1.28 (0.75–2.17), 0.334, 0.79 (0.79–0.80)
Null/G 0 (–) 2 (0.3, 0.1 to 0.7) –, 0.462, 0.79 (0.79–0.79)
Null/A 0 (–) 0 (–) —
HMOX 2 rs1051308 A/A 102 (50.5, 43.6–57.4) 310 (41.5, 38.0–45.0) 1.44 (1.04–1.99), 0.022,

0.81 (0.79–0.84)
A/G 85 (42.1, 35.3–48.9) 333 (44.6, 41.0–48.1) 0.90 (0.65–1.25), 0.526, 0.78 (0.76–0.80)
G/G 15 (7.4, 3.8–11.0) 102 (13.7, 11.2–16.1) 0.51 (0.28–0.92), 0.017,

0.78 (0.7–0.79)
Null/A 0 (–) 1 (0.1, 0.1 to 0.4) –, 0.603, 0.79 (0.79–79)
Null/G 0 (–) 1 (0.1, 0.1 to 0.4) –, 0.603, 0.79 (0.79–0.79)
Alleles
HMOX1 rs2071746 A 238 (58.9, 54.1–63.7) 777 (52.1, 49.5–54.6) 1.32 (1.05–1.66), 0.015,y 0.81 (0.79–0.83)
T 166 (41.1, 36.3–45.9) 715 (47.9, 45.4–50.5) 0.76 (0.60–0.95), 0.015,y 0.77 (0.75–0.78)
HMOX1 rs2071747 G 391 (96.8, 95.1–98.5) 1425 (95.5, 94.5–96.6) 1.41 (0.75–2.72), 0.259, 0.84 (0.74–0.91)
C 13 (3.2, 1.5–4.9) 67 (4.5, 3.4–5.5) 0.71 (0.37–1.33), 0.59, 0.79 (0.78–0.79)
HMOX2 rs2270363 G 271 (67.1, 62.5–71.7) 1039 (69.6, 67.3–72.0) 0.89 (0.70–1.13), 0.354, 0.77 (0.74–0.80)
A 133 (32.9, 28.3–37.5) 453 (30.4, 28.0–32.7) 1.13 (0.88–1.43), 0.354, 0.79 (0.78–0.81)
HMOX 2 rs1051308 A 289 (71.5, 67.1–75.9) 954 (63.9, 61.5–66.4) 1.42 (1.11–1.82), 0.004,z 0.82 (0.80–0.85)
G 115 (28.5, 24.1–32.9) 538 (36.1, 33.6–38.5) 0.71 (0.55–0.90), 0.004,z 0.77 (0.76–0.78)
Null HMOX1 0 (–) 2 (0.1, 0.1 to 0.3) –, 0.462, 0.79 (0.79–0.79)
Null HMOX 2 0 (–) 2 (0.1, 0.1 to 0.3) –, 0.462, 0.79 (0.79–0.79)
The values in each cell represent number (percentage, 95% CIs). CI¼ confidence interval, ET¼ essential tremor, HMOX¼ heme oxygenase,
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containing lead, mercury, manganese, solvents, and b-carbo-
lines (toxins that produce tremor), and exposure to agricultural
work, well water, pesticides, and cigarette smoking and alcohol
drinking habits in patients with ET compared with controls.
After a multivariate study, exposure to agricultural work and
frosted glass, were significantly associated to the risk for ET,
whereas age at onset of ET was significantly higher in patients
exposed to iron–manganese alloys.22
Blood harmane (a potent tremor-inducing b-carboline
alkaloid, which shares structural similarity with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin responsible for
development of one of the main animal models or PD) levels
have been found increased in patients with ET.25,26 In addition,
a recent postmortem study described increased cerebellum
harmane levels in ET patients compared with controls as well.27
Lead levels have also been found increased in ET patients
compared with controls28,29 and were related with the risk for
ET in interaction with an d-amino-levulinic acid dehydratase
gene polymorphism.30 Exposures to nutritional antioxidant
intake in the current diet were similar for ET patients and
controls in a single study regarding this issue.31
The pathophysiology and neuropathology of ET are not well
established. Together with the traditional olivary model of ET
(tremor should be generated by pacemaking neurons in the inferior
olivary nucleus with rhythmic firing and an abnormal cerebellar
output) recent evidences based in rigorous neuropathological
studies suggested a cerebellar degenerative model with a partial
loss of Purkinje cells, changes in Purkinje cell morphology, and
alterations in connected neuronal populations.32
A recent study with magnetic resonance imaging T2-
relaximetry, involving 24 ET patients and 25 age-matched
healthy controls, found increased iron content in both globus
pallidus, in both substantia nigra, and in the right dentate nucleus
of the cerebellum of ET patients (although only bilateral pallidum
remained significant after correction for multiple comparisons).33
To our knowledge, neither iron content or HMOX1 and HMOX2
expression have been measured in neuropathological studies of
ET patients yet. It could be proposed that if the iron content should
be increased in the cerebellum, HMOX should act as protective
against iron-related oxidative stress, and alterations in HMOX1
and HMOX2 genes could be related with the cerebellar neuro-
degenerative model of the pathogenesis of ET.
Although the results of the present study should be taken
with caution (a main limitation is the low sample size) and
deserve further replication studies in other populations, they
suggest a slightly decreased risk for ET in Spanish white
individuals carrying the HMOX1 rs2021746T and HMOX2
rs1051308G allele variants.
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